Investment Opportunity
A new modality for drug-resistant disease.
TheraStel is pioneering a focused bioelectric therapeutic platform targeting one of oncology’s persistent challenges: resistance to treatment. By shifting the paradigm from biochemical inhibition to localized bioelectric modulation, SIHD creates a differentiated path for therapeutic development.
First-in-Class Approach
Bioelectric modulation as a therapeutic modality
De-risked Compound Strategy
Repurposed molecule strategy with localized delivery
Targeted Delivery Advantage
SIHD-enabled delivery designed to reduce systemic exposure
Partners
Consultant
Consulting
Manufacturing
Pre-Clinical
Testing
Clinical
Testing
Current Status
01
Financial Stage
Pre-seed funding - $5M
✔ Pre-clinical efficacy & safety
✔ IND-enabling studies complete
✔ IND submission (FDA)
✔ Series A readiness
02
Program Milestones
SIHD - CZX
✔ Pre-Seed Funding
✔ Published initial study
✔ Evaluating CDMO manufacturing
03
partners and investors
Spinout: MUSC
Innosphere Incubator Program
04
Future Programs
Coming Soon!
